Jiangxi Dongyan Pharmaceutical Co., Ltd., established on December 21, 2006, is a national medium-sized industrial enterprise engaged in the research, development, and production of two main categories: pharmaceutical raw materials, intermediates, as well as anhydrous hydrogen fluoride and inorganic fluoride salts. The company is located in the Fine Chemical Industrial Park of Yanshan County Industrial Park, Jiangxi Province, with a total investment of 145.1754 million yuan, covering an area of 215 acres, and an internal greening rate of 40%.

The company's main products include: an annual production of 400 tons of pharmaceutical intermediate 1-methyl-5-mercaptotetrazole, 30,000 tons of high-purity anhydrous hydrogen fluoride, 10,000 tons of ammonium bifluoride (industrial grade), and 4,000 tons of ammonium fluoride (industrial grade).

Adhering to the quality policy of "Customer First, Full Participation, Standardization and Rigor, Innovation and Development," the company has established a robust quality assurance system, passed ISO9000 Quality Management System and ISO14001 Environmental Management System certifications. More importantly, our products have gained widespread trust from domestic and international clients, which is an unparalleled honor.

The company has always maintained a strong social reputation. Since its establishment, it has been named by the provincial government as a "Key Development Enterprise of Jiangxi Province" and a "Contract-Honoring and Creditworthy Enterprise." It has also been consistently rated as a top "AAA" credit enterprise for many years by its account-opening bank—the Industrial and Commercial Bank of China, Yanshan County Branch, Shangrao City.

Located in an area abundant with fluorite resources, the company enjoys raw material advantages. The plant site is about 5 kilometers from the Yanshan County exit of the Shanghai-Kunming Expressway and approximately 13 kilometers from the Hengfeng Freight Station of the Fengfu Railway Line, providing transportation advantages. Over the years, the company has continuously increased investment in high-tech initiatives and established long-term, positive cooperative relationships with research institutions such as the Sichuan Institute of Antibiotics, Shanghai Institute of Pharmaceutical Industry, and Tianjin Institute of Pharmaceutical Research. This ensures that the R&D level of the company's technology center remains domestically leading in the industry, highlighting its technical advantages.

Our company will continue to be guided by domestic and international market demands, rely on technological progress, fully leverage our advantages, and wholeheartedly provide customers with more high-quality products and services. We are also willing to cooperate with friends from all sectors for mutual development.